Onconetix (ONCO) Competitors $3.00 +0.06 (+2.04%) Closing price 04:00 PM EasternExtended Trading$2.98 -0.02 (-0.53%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. NKGN, APLM, PPBT, GNPX, KTTA, HCWB, AEZS, VYNE, SPRB, and THARShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include NKGen Biotech (NKGN), Apollomics (APLM), Purple Biotech (PPBT), Genprex (GNPX), Pasithea Therapeutics (KTTA), HCW Biologics (HCWB), Aeterna Zentaris (AEZS), VYNE Therapeutics (VYNE), Spruce Biosciences (SPRB), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Its Competitors NKGen Biotech Apollomics Purple Biotech Genprex Pasithea Therapeutics HCW Biologics Aeterna Zentaris VYNE Therapeutics Spruce Biosciences Tharimmune Onconetix (NASDAQ:ONCO) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Is ONCO or NKGN more profitable? NKGen Biotech has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. NKGen Biotech's return on equity of 0.00% beat Onconetix's return on equity.Company Net Margins Return on Equity Return on Assets Onconetix-3,327.03% -192.74% -89.55% NKGen Biotech N/A N/A -479.36% Do insiders & institutionals hold more shares of ONCO or NKGN? 23.9% of Onconetix shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 3.1% of Onconetix shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to ONCO or NKGN? In the previous week, Onconetix had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for NKGen Biotech. Onconetix's average media sentiment score of 1.88 beat NKGen Biotech's score of 0.00 indicating that Onconetix is being referred to more favorably in the media. Company Overall Sentiment Onconetix Very Positive NKGen Biotech Neutral Which has more volatility and risk, ONCO or NKGN? Onconetix has a beta of 3.37, indicating that its stock price is 237% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Which has better valuation & earnings, ONCO or NKGN? Onconetix has higher revenue and earnings than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnconetix$2.52M1.85-$58.69MN/AN/ANKGen BiotechN/AN/A-$82.94M-$2.45-0.05 SummaryOnconetix beats NKGen Biotech on 6 of the 10 factors compared between the two stocks. Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.54M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.0831.2626.59Price / Sales1.85400.78464.64173.43Price / CashN/A44.6737.7359.36Price / Book0.798.0910.046.68Net Income-$58.69M-$54.08M$3.27B$265.59M7 Day Performance6.76%2.25%3.17%3.42%1 Month Performance-19.14%3.41%4.34%1.09%1 Year Performance-99.37%18.61%44.12%23.84% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix1.1129 of 5 stars$3.00+2.0%N/A-99.4%$4.54M$2.52M0.0012Positive NewsNKGNNKGen BiotechN/A$0.13-5.4%N/A-80.7%$5.96MN/A-0.03N/AAPLMApollomics0.6767 of 5 stars$5.40-5.2%N/A-53.6%$5.94M$1.49M0.0045Positive NewsGap DownPPBTPurple Biotech1.8476 of 5 stars$2.23-1.8%$33.00+1,379.8%N/A$5.78MN/A-5.3120News CoverageGap DownGNPXGenprex1.861 of 5 stars$0.17-10.9%N/A-75.4%$5.64MN/A0.0020Positive NewsKTTAPasithea Therapeutics1.4381 of 5 stars$0.71-0.3%N/A-83.7%$5.28MN/A-0.093News CoveragePositive NewsGap UpHCWBHCW Biologics2.5252 of 5 stars$3.63-9.7%$35.00+864.2%-68.0%$5.25M$2.57M-0.1640Gap UpAEZSAeterna ZentarisN/A$2.85-18.6%N/A-24.2%$5.11M$2.37M-0.1920Gap DownHigh Trading VolumeVYNEVYNE Therapeutics2.543 of 5 stars$0.33-3.2%$6.25+1,776.9%-81.9%$5.07M$500K-0.3730Gap DownSPRBSpruce Biosciences1.7008 of 5 stars$8.95-0.7%$131.25+1,366.5%-78.8%$5.03M$4.91M-9.5220THARTharimmune3.4424 of 5 stars$1.20-8.1%$17.00+1,322.6%+68.1%$4.94MN/A-0.192 Related Companies and Tools Related Companies NKGN Alternatives APLM Alternatives PPBT Alternatives GNPX Alternatives KTTA Alternatives HCWB Alternatives AEZS Alternatives VYNE Alternatives SPRB Alternatives THAR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access